OtherEditorial
To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy
Sandy Srinivas and Andrei Iagaru
Journal of Nuclear Medicine August 2021, jnumed.121.263035; DOI: https://doi.org/10.2967/jnumed.121.263035
Sandy Srinivas
Stanford University, United States
Andrei Iagaru
Stanford University, United States
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy
Sandy Srinivas, Andrei Iagaru
Journal of Nuclear Medicine Aug 2021, jnumed.121.263035; DOI: 10.2967/jnumed.121.263035
Jump to section
Related Articles
- No related articles found.
Cited By...
- Is 18F-FDG PET Needed to Assess 177Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis
- Clinical Trials of Prostate-Specific Membrane Antigen Radiopharmaceutical Therapy
- 177Lu-PSMA Therapy
- Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial
- The VISION Forward: Recognition and Implication of PSMA-/18F-FDG+ mCRPC
- A VISION of ALSYMPCA